+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nuclear Energy - Global Strategic Business Report

  • PDF Icon

    Report

  • 375 Pages
  • October 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 6106411
The global market for Nuclear Energy was valued at US$36.2 Billion in 2025 and is projected to reach US$44.9 Billion by 2032, growing at a CAGR of 3.1% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Nuclear Energy Market - Key Trends & Drivers Summarized

Why Is Nuclear Energy Regaining Strategic Importance Worldwide?

Nuclear energy is experiencing renewed global interest as countries seek stable, low-emission sources of electricity to meet decarbonization goals and energy security needs. Unlike fossil fuels, nuclear plants offer consistent baseload power without carbon emissions, making them a key element in long-term climate strategies. As more economies face volatile fuel markets and the limitations of intermittent renewables, nuclear energy is being reconsidered as a critical complement to solar and wind.

Several nations are extending the life of existing reactors, restarting previously halted projects, and exploring new technologies such as small modular reactors. Public and policy sentiment is shifting in favor of nuclear in many regions, especially where grids require steady power to balance renewable inputs. This policy shift is supported by energy transition frameworks that include nuclear as part of clean energy portfolios.

How Are Technological Innovations Reshaping the Nuclear Landscape?

Modern reactor technologies are redefining safety, scalability, and deployment flexibility in the nuclear sector. Small modular reactors (SMRs) and advanced Generation IV designs promise improved safety through passive cooling systems, simplified construction, and reduced waste generation. These reactors can be deployed in smaller grids, remote locations, or industrial clusters, expanding the relevance of nuclear energy beyond traditional large-scale applications.

Digital monitoring systems, predictive maintenance tools, and next-generation control infrastructure are improving plant efficiency and lifecycle management. Innovations in fuel design, including accident-tolerant fuels and thorium-based alternatives, are also gaining traction. These advancements aim to address public concerns around safety and waste, while lowering construction timelines and operational costs. Coupled with standardized licensing and modular construction, technology is playing a central role in making nuclear energy more accessible and acceptable.

What Economic and Geopolitical Factors Are Driving Investment?

Global energy markets are being shaped by supply chain disruptions, rising fuel costs, and shifting geopolitical alliances. In this environment, nuclear energy offers a means to reduce dependence on imported fossil fuels, particularly in regions facing energy security risks. Government-led financing programs, international collaborations, and multilateral support are being mobilized to accelerate deployment of nuclear infrastructure.

In parallel, power utilities and grid operators are evaluating long-term cost stability, which favors nuclear assets with low marginal operating costs and long plant life. As economic models for clean energy evolve, nuclear projects are increasingly eligible for green financing, especially when tied to emissions reduction targets. Some countries are also leveraging nuclear energy to power hydrogen production and industrial decarbonization, further embedding it in broader energy transition strategies.

Growth in the nuclear energy market is driven by several factors.

Rising demand for low-carbon baseload power is encouraging the extension and expansion of nuclear infrastructure. Advancements in small modular and advanced reactor technologies are making nuclear more flexible, safe, and deployable in new contexts. Supportive energy transition policies and financial incentives are enabling new project development and life extension of existing plants. Geopolitical emphasis on energy independence and long-term fuel security is pushing governments to reinvest in nuclear capacity. Integration of nuclear with hydrogen production, desalination, and industrial heat applications is broadening its role in clean energy systems. These combined factors are positioning nuclear energy as a stable, scalable, and low-emission component of the future energy mix.

Report Scope

The report analyzes the Nuclear Energy market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Type (Pressurized Water Reactor, Boiling Water Reactor, Fast Breeder Reactor, Advanced Gas Cooled Reactor, Uranium Reactor); Fuel (Uranium-235, Uranium-233, Plutonium-239); Application (Energy Application, Defense Application, Other Applications)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Pressurized Water Reactor segment, which is expected to reach US$18.4 Billion by 2032 with a CAGR of a 3.7%. The Boiling Water Reactor segment is also set to grow at 3.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $9.9 Billion in 2025, and China, forecasted to grow at an impressive 5.6% CAGR to reach $8.9 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Nuclear Energy Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Nuclear Energy Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Nuclear Energy Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Areva (Framatome/EDF), Babcock & Wilcox (BWX Technologies), Cameco Corporation, China General Nuclear Power Group (CGN), Constellation Energy Corporation and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Nuclear Energy market report include:

  • Areva (Framatome/EDF)
  • Babcock & Wilcox (BWX Technologies)
  • Cameco Corporation
  • China General Nuclear Power Group (CGN)
  • Constellation Energy Corporation
  • Doosan Enerbility
  • EDF (Électricité de France)
  • Framatome
  • GE Vernova / GE Hitachi Nuclear Energy
  • Holtec International
  • Korea Electric Power Corporation (KEPCO)
  • Korea Hydro & Nuclear Power
  • Mitsubishi Heavy Industries
  • NuScale Power
  • Orano
  • Rosatom
  • Shaw (previously Westinghouse Electric Co.)
  • TerraPower
  • Toshiba Energy Systems & Solutions
  • Urenco Group

What Sets This Report Apart From Others?

  • Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
  • Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
  • Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
  • Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
  • Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
  • Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • World Market Trajectories
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Nuclear Pharmacy - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Demand for Targeted Diagnostic Imaging Drives Growth in Nuclear Pharmacy Services
  • Expansion of PET and SPECT Imaging in Oncology, Cardiology, and Neurology Boosts Radiopharmaceutical Usage
  • Increased Availability of Short-Lived Isotopes Spurs Growth in Centralized and In-Hospital Nuclear Pharmacies
  • Advancements in Cyclotron and Generator Technologies Enhance On-Demand Radiotracer Production
  • Regulatory Approvals for New Radiolabeled Drugs Strengthen Market for Precision Diagnostic Tools
  • Shift Toward Personalized Medicine Throws the Spotlight on Radiotheranostics and Companion Diagnostics
  • Growing Use of Radiopharmaceuticals in Therapeutic Applications Expands Scope of Nuclear Pharmacy Operations
  • Integration of Automation and Robotics in Radiopharmacies Improves Accuracy, Safety, and Throughput
  • Expansion of Academic and Clinical Research Programs Fuels Demand for Custom Radiopharmaceutical Compounding
  • Rising Incidence of Chronic and Age-Related Diseases Accelerates Investment in Nuclear Imaging Infrastructure
  • Improvements in Cold-Chain Logistics and Dose Scheduling Support Wider Distribution of Time-Sensitive Isotopes
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Nuclear Pharmacy Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for Nuclear Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for Institutional Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Institutional Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Institutional Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Commercial Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Commercial Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Commercial Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Therapeutic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
  • Table 17: USA Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 18: USA Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 19: USA 13-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2020, 2026 & 2032
  • Table 20: USA Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 21: USA Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 22: USA 13-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2020, 2026 & 2032
CANADA
  • Table 23: Canada Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 24: Canada Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 25: Canada 13-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2020, 2026 & 2032
  • Table 26: Canada Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 27: Canada Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 28: Canada 13-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2020, 2026 & 2032
JAPAN
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
  • Table 29: Japan Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 30: Japan Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 31: Japan 13-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2020, 2026 & 2032
  • Table 32: Japan Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 33: Japan Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 34: Japan 13-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2020, 2026 & 2032
CHINA
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
  • Table 35: China Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 36: China Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 37: China 13-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2020, 2026 & 2032
  • Table 38: China Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 39: China Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 40: China 13-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2020, 2026 & 2032
EUROPE
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
  • Table 41: Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 42: Europe Historic Review for Nuclear Pharmacy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 43: Europe 13-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
  • Table 44: Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 45: Europe Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 46: Europe 13-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2020, 2026 & 2032
  • Table 47: Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 48: Europe Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 49: Europe 13-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2020, 2026 & 2032
FRANCE
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
  • Table 50: France Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 51: France Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 52: France 13-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2020, 2026 & 2032
  • Table 53: France Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 54: France Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 55: France 13-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2020, 2026 & 2032
GERMANY
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
  • Table 56: Germany Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 57: Germany Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 58: Germany 13-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2020, 2026 & 2032
  • Table 59: Germany Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 60: Germany Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 61: Germany 13-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2020, 2026 & 2032
ITALY
  • Table 62: Italy Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 63: Italy Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 64: Italy 13-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2020, 2026 & 2032
  • Table 65: Italy Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 66: Italy Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 67: Italy 13-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2020, 2026 & 2032
UNITED KINGDOM
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
  • Table 68: UK Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 69: UK Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 70: UK 13-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2020, 2026 & 2032
  • Table 71: UK Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 72: UK Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 73: UK 13-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2020, 2026 & 2032
SPAIN
  • Table 74: Spain Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 75: Spain Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 76: Spain 13-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2020, 2026 & 2032
  • Table 77: Spain Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 78: Spain Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 79: Spain 13-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2020, 2026 & 2032
RUSSIA
  • Table 80: Russia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 81: Russia Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 82: Russia 13-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2020, 2026 & 2032
  • Table 83: Russia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 84: Russia Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 85: Russia 13-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2020, 2026 & 2032
REST OF EUROPE
  • Table 86: Rest of Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 87: Rest of Europe Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 88: Rest of Europe 13-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2020, 2026 & 2032
  • Table 89: Rest of Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 90: Rest of Europe Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 91: Rest of Europe 13-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2020, 2026 & 2032
ASIA-PACIFIC
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
  • Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 93: Asia-Pacific Historic Review for Nuclear Pharmacy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 94: Asia-Pacific 13-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
  • Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 96: Asia-Pacific Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 97: Asia-Pacific 13-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2020, 2026 & 2032
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 100: Asia-Pacific 13-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2020, 2026 & 2032
AUSTRALIA
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
INDIA
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Areva (Framatome/EDF)
  • Babcock & Wilcox (BWX Technologies)
  • Cameco Corporation
  • China General Nuclear Power Group (CGN)
  • Constellation Energy Corporation
  • Doosan Enerbility
  • EDF (Électricité de France)
  • Framatome
  • GE Vernova / GE Hitachi Nuclear Energy
  • Holtec International
  • Korea Electric Power Corporation (KEPCO)
  • Korea Hydro & Nuclear Power
  • Mitsubishi Heavy Industries
  • NuScale Power
  • Orano
  • Rosatom
  • Shaw (previously Westinghouse Electric Co.)
  • TerraPower
  • Toshiba Energy Systems & Solutions
  • Urenco Group

Table Information